1. The acquisition will allow Stryker to supplement its portfolio with a complete meniscal platform. Ivy Sports Medicine had the “only FDA-approved collagen meniscus implant on the market.”
2. Stryker said Ivy’s portfolio was highly complementary to their current markets.
“Ivy’s complete meniscal platform, coupled with their clinical history, will allow us to provide our customers with multiple solutions to address meniscal repair,” Vice President and General Manager of Stryker’s Sports Medicine business Matt Moreau said.
More news on orthopedic and spinal devices:
Alphatec closes $80M sale of international operations to Globus, focuses on future growth: 7 key notes
American Joint Replacement Registry and Q-Centrix partner to improve data submission efficiency: 3 takeaways
Medtronic, Stryker and Smith & Nephew dominate MIS instruments market — 6 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
